Zhejiang Tailison Pharmaceutical Co. Ltd. (浙江泰利森药业有限公司)

概览

关联

2

项与浙江泰利森药业有限公司相关的临床试验

CTR20250991

/ Active, not recruitingN/A

甲磺酸溴隐亭片在健康受试者中随机、开放、单剂量、四周期、两序列、完全重复交叉的餐后状态下生物等效性试验

主要研究目的研究餐后状态下单次口服受试制剂甲磺酸溴隐亭片（规格：2.5mg，浙江泰利森药业有限公司）与参比制剂甲磺酸溴隐亭片（商品名：Parlodel®，规格：2.5mg；DOPPEL Farmaceutici S.r.l.公司生产）在健康成年受试者体内的药代动力学，评价餐后状态口服两种制剂的生物等效性。次要研究目的研究受试制剂甲磺酸溴隐亭片和参比制剂甲磺酸溴隐亭片（Parlodel®）在健康成年受试者中的安全性。

开始日期2025-04-13

申办/合作机构

浙江泰利森药业有限公司

CTR20222700

/ CompletedN/A

甲磺酸溴隐亭片在健康受试者中随机、开放、单剂量、四周期、两序列、完全重复交叉的餐后状态下生物等效性试验

1、主要研究目的：研究餐后状态下单次口服受试制剂甲磺酸溴隐亭片（规格：2.5mg，浙江泰利森药业有限公司）与参比制剂甲磺酸溴隐亭片（商品名：Parlodel®，规格：2.5mg；DOPPEL Farmaceutici S.r.l.公司生产）在健康成年受试者体内的药代动力学，评价餐后状态口服两种制剂的生物等效性。 2、次要研究目的：研究受试制剂甲磺酸溴隐亭片和参比制剂甲磺酸溴隐亭片（Parlodel®）在健康成年受试者中的安全性。

开始日期2022-11-17

申办/合作机构

浙江泰利森药业有限公司

100 项与浙江泰利森药业有限公司相关的临床结果

登录后查看更多信息

0 项与浙江泰利森药业有限公司相关的专利（医药）

登录后查看更多信息

2

项与浙江泰利森药业有限公司相关的文献（医药）

Zhongguo Fenti Jishu

Preparation of ultrafine glimepiride powders and dissolution improvement of glimepiride tablets

作者: Cui, Shengfa ; Wen, Jun ; Xiao, Yabao

The aim is to prepare ultrafine glimepiride powders and improve the dissolution in vitro of glimepiride tablets.The ultrafine glimepiride powders were made by jet mill.The dissolution curve of glimepiride tablets was determined by the method of high performance liquid chromatog.The similarity was evaluated with the reference preparation of glimepiride tablets using the similarity factor f₂ method referred by the U. S. Food and Drug Administration.The results showed that the median diameter d₅₀ of ultrafine powders was 1.30 μm.The distribution of particle size was between 0.40 and 5.85 μm.The similarity factors of dissolution curves of three batches of tablets were resp. 54.0, 57.7 and 53.6.The dissolution in vitro of glimepiride tablets was improved by micronization.The dissolution action was similar with that of the reference preparation

Zhongguo Xiandai Yingyong Yaoxue

Determination of scutellarin in Dengzhan Huasu tablets by HPLC

作者: Zhu, Hui-ping ; Xiao, Ya-bao

Scutellarin in Dengzhan Huasu tablets was determinedHPLC was used, column: DS-C₁₈ mobile phase: methanol-tetrahydrofuran-0.3% phosphoric acid (12:13:75), wave length: 335 nm.The linear range was 10-100 μg/mL (r = 0.9999), recovery rate was 99.49%, RSD = 1.13%.The method is rapid, simple, and accurate.

100 项与浙江泰利森药业有限公司相关的药物交易

登录后查看更多信息

100 项与浙江泰利森药业有限公司相关的转化医学

登录后查看更多信息